grandma/cannon: also don't forget that the guy at Goshen who approached BOCX (Dr. Schwartzentruber) is on the editorial board of the American Journal of Oncology Review. That is the JAMA of oncology. I've spoken directly with Dr. Schwartzentruber and asked him if he would be publishing studies in the big journals...he said "that's the whole point of what we do." For those of you that weren't around when I reported on my conversation with Dr. Schwarzentruber, he also said that Goshen's focus would be almost entirely on the imaging aspects of RECAF. He said a "major company" is already running with the diagnostic application. And by the way, this guy contacted BOCX out of the blue after seeing their prelim data not the other way around. Aside from his ties to the leading oncology peer-reviewed journal, his grounding is 100% in clinical trials. This guy spent 13 years as a senior investigator for NIH ("investigator" meaning clinical trial investigator), which is by far the largest operator of clinical trials in the world.
"Dr. Douglas Schwartzentruber is a surgical oncologist who completed a fellowship in Immunotherapy at the National Cancer Institute, Bethesda, Maryland where he subsequently worked for 13 years as a Senior Investigator. Dr. Schwartzentruber's research on the role of vaccines in the treatment of malignant melanoma, has gained both national and international attention. He serves on the editorial board for the American Journal of Oncology Review and the Journal of Translational Medicine."
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.
